KORU Medical Systems (KRMD) Stock Price
KORU Medical Systems Price
Revenue has compounded at 18.1% per year over the past 19 years to 41.13 M USD. Earnings per share have declined at 6.5% per year over the last 11 years. KORU Medical Systems's net margin stands at -6.4%, up from -19.4% several years earlier. Analysts set a median price target of 7.14 USD, implying 73.3% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 26% above its 52-week low.
KORU Medical Systems stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of KORU Medical Systems over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how KORU Medical Systems stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing KORU Medical Systems's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | KORU Medical Systems Price |
|---|---|
| 8/5/2026 | 4.12 USD |
| 8/4/2026 | 4.22 USD |
| 8/3/2026 | 4.23 USD |
| 7/31/2026 | 4.11 USD |
| 7/30/2026 | 4.11 USD |
| 7/29/2026 | 4.05 USD |
| 7/27/2026 | 3.90 USD |
| 7/23/2026 | 3.73 USD |
| 7/22/2026 | 3.86 USD |
| 7/21/2026 | 4.03 USD |
| 7/20/2026 | 4.06 USD |
| 7/17/2026 | 4.11 USD |
| 7/16/2026 | 4.24 USD |
| 7/15/2026 | 4.13 USD |
| 7/14/2026 | 4.15 USD |
| 7/13/2026 | 4.28 USD |
| 7/10/2026 | 4.28 USD |
| 7/9/2026 | 4.43 USD |
| 7/8/2026 | 4.44 USD |
| 7/7/2026 | 4.59 USD |
| 7/6/2026 | 4.53 USD |
| 7/2/2026 | 4.49 USD |
| 7/1/2026 | 4.40 USD |
| 6/30/2026 | 4.20 USD |
| 6/29/2026 | 4.37 USD |
| 6/26/2026 | 4.46 USD |
| 6/25/2026 | 4.28 USD |
| 6/24/2026 | 4.19 USD |
| 6/23/2026 | 4.13 USD |
| 6/22/2026 | 3.86 USD |
| 6/18/2026 | 3.90 USD |
| 6/17/2026 | 3.88 USD |
| 6/16/2026 | 3.94 USD |
| 6/15/2026 | 3.87 USD |
| 6/12/2026 | 4.00 USD |
| 6/11/2026 | 4.00 USD |
| 6/10/2026 | 4.01 USD |
| 6/9/2026 | 4.00 USD |
| 6/8/2026 | 3.99 USD |
| 6/5/2026 | 3.93 USD |
| 6/4/2026 | 4.14 USD |
| 6/3/2026 | 3.92 USD |
| 6/2/2026 | 4.05 USD |
| 6/1/2026 | 4.07 USD |
| 5/29/2026 | 4.06 USD |
| 5/28/2026 | 4.18 USD |
| 5/27/2026 | 4.15 USD |
| 5/26/2026 | 4.20 USD |
| 5/22/2026 | 4.10 USD |
| 5/21/2026 | 4.14 USD |
| 5/20/2026 | 4.00 USD |
| 5/19/2026 | 3.96 USD |
| 5/18/2026 | 3.83 USD |
| 5/15/2026 | 3.90 USD |
| 5/14/2026 | 3.98 USD |
| 5/13/2026 | 3.85 USD |
| 5/11/2026 | 4.02 USD |
| 5/8/2026 | 4.20 USD |
| 5/7/2026 | 4.44 USD |
| 5/6/2026 | 4.01 USD |
| 5/5/2026 | 4.08 USD |
| 4/23/2026 | 4.05 USD |
| 4/22/2026 | 4.11 USD |
| 4/21/2026 | 4.02 USD |
| 4/20/2026 | 4.26 USD |
| 4/17/2026 | 4.33 USD |
| 4/16/2026 | 4.18 USD |
| 4/15/2026 | 4.25 USD |
| 4/14/2026 | 4.30 USD |
| 4/13/2026 | 4.34 USD |
| 4/10/2026 | 4.21 USD |
| 4/9/2026 | 4.37 USD |
| 4/8/2026 | 4.19 USD |
| 4/7/2026 | 4.24 USD |
| 4/6/2026 | 4.26 USD |
| 4/2/2026 | 4.32 USD |
| 4/1/2026 | 4.27 USD |
| 3/31/2026 | 4.32 USD |
| 3/30/2026 | 4.25 USD |
| 3/27/2026 | 4.22 USD |
| 3/26/2026 | 4.36 USD |
| 3/25/2026 | 4.41 USD |
| 3/24/2026 | 4.40 USD |
| 3/23/2026 | 4.43 USD |
| 3/20/2026 | 4.21 USD |
| 3/19/2026 | 4.30 USD |
| 3/18/2026 | 4.35 USD |
| 3/17/2026 | 4.27 USD |
| 3/16/2026 | 4.29 USD |
| 3/13/2026 | 4.28 USD |
| 3/12/2026 | 4.31 USD |
| 3/11/2026 | 4.51 USD |
| 3/10/2026 | 4.53 USD |
| 3/9/2026 | 4.61 USD |
| 3/6/2026 | 4.55 USD |
| 3/5/2026 | 4.64 USD |
| 3/4/2026 | 4.85 USD |
| 3/3/2026 | 4.77 USD |
| 3/2/2026 | 4.87 USD |
| 2/27/2026 | 4.77 USD |
| 2/26/2026 | 4.95 USD |
| 2/25/2026 | 4.92 USD |
| 2/24/2026 | 4.77 USD |
| 2/23/2026 | 4.79 USD |
| 2/20/2026 | 4.74 USD |
| 2/19/2026 | 4.69 USD |
| 2/18/2026 | 4.70 USD |
| 2/17/2026 | 4.67 USD |
| 2/13/2026 | 4.67 USD |
| 2/12/2026 | 4.37 USD |
| 2/11/2026 | 4.56 USD |
| 2/10/2026 | 4.67 USD |
| 2/9/2026 | 4.78 USD |
| 2/6/2026 | 4.92 USD |
| 2/5/2026 | 4.87 USD |
| 2/4/2026 | 5.09 USD |
| 2/3/2026 | 5.52 USD |
| 2/2/2026 | 5.69 USD |
| 1/30/2026 | 5.39 USD |
| 1/29/2026 | 5.45 USD |
| 1/28/2026 | 5.52 USD |
| 1/27/2026 | 5.68 USD |
| 1/26/2026 | 5.63 USD |
| 1/23/2026 | 5.61 USD |
| 1/22/2026 | 5.68 USD |
| 1/21/2026 | 5.70 USD |
| 1/20/2026 | 5.58 USD |
| 1/16/2026 | 5.51 USD |
| 1/15/2026 | 5.67 USD |
| 1/14/2026 | 5.57 USD |
| 1/13/2026 | 5.78 USD |
| 1/12/2026 | 5.89 USD |
| 1/9/2026 | 5.65 USD |
| 1/8/2026 | 5.81 USD |
| 1/7/2026 | 5.62 USD |
| 1/6/2026 | 5.59 USD |
| 1/5/2026 | 5.57 USD |
| 1/2/2026 | 5.61 USD |
| 12/31/2025 | 5.81 USD |
| 12/30/2025 | 5.69 USD |
| 12/29/2025 | 6.06 USD |
| 12/26/2025 | 6.23 USD |
| 12/24/2025 | 6.48 USD |
| 12/23/2025 | 6.52 USD |
| 12/22/2025 | 6.07 USD |
| 12/19/2025 | 5.80 USD |
| 12/18/2025 | 5.75 USD |
| 12/17/2025 | 5.51 USD |
| 12/16/2025 | 5.77 USD |
| 12/15/2025 | 5.81 USD |
| 12/12/2025 | 5.78 USD |
| 12/11/2025 | 5.86 USD |
| 12/10/2025 | 5.89 USD |
| 12/9/2025 | 5.76 USD |
| 12/8/2025 | 5.73 USD |
| 12/5/2025 | 5.57 USD |
| 12/4/2025 | 5.68 USD |
| 12/3/2025 | 5.72 USD |
| 12/2/2025 | 5.68 USD |
| 12/1/2025 | 5.82 USD |
| 11/28/2025 | 5.92 USD |
| 11/26/2025 | 5.80 USD |
| 11/25/2025 | 5.25 USD |
| 11/24/2025 | 4.89 USD |
| 11/21/2025 | 4.78 USD |
| 11/20/2025 | 4.40 USD |
| 11/19/2025 | 4.35 USD |
| 11/18/2025 | 4.47 USD |
| 11/17/2025 | 4.49 USD |
| 11/14/2025 | 4.32 USD |
| 11/13/2025 | 4.35 USD |
| 11/12/2025 | 3.78 USD |
| 11/11/2025 | 3.73 USD |
| 11/10/2025 | 3.92 USD |
| 11/7/2025 | 3.90 USD |
| 11/6/2025 | 3.96 USD |
| 11/5/2025 | 4.03 USD |
| 11/4/2025 | 3.86 USD |
| 11/3/2025 | 3.84 USD |
| 10/31/2025 | 3.96 USD |
| 10/30/2025 | 3.90 USD |
| 10/29/2025 | 3.95 USD |
| 10/28/2025 | 4.01 USD |
| 10/27/2025 | 4.13 USD |
| 10/24/2025 | 4.24 USD |
| 10/23/2025 | 4.25 USD |
| 10/22/2025 | 4.25 USD |
| 10/21/2025 | 4.19 USD |
| 10/20/2025 | 4.14 USD |
| 10/17/2025 | 4.05 USD |
| 10/16/2025 | 4.02 USD |
| 10/15/2025 | 4.08 USD |
| 10/14/2025 | 4.14 USD |
| 10/13/2025 | 4.07 USD |
| 10/10/2025 | 4.29 USD |
| 10/9/2025 | 4.27 USD |
| 10/8/2025 | 4.19 USD |
| 10/7/2025 | 3.93 USD |
| 10/6/2025 | 3.96 USD |
| 10/3/2025 | 3.85 USD |
| 10/2/2025 | 3.78 USD |
| 10/1/2025 | 3.81 USD |
| 9/30/2025 | 3.83 USD |
| 9/29/2025 | 3.84 USD |
| 9/26/2025 | 3.96 USD |
| 9/25/2025 | 3.92 USD |
| 9/24/2025 | 3.95 USD |
| 9/23/2025 | 4.03 USD |
| 9/22/2025 | 4.02 USD |
| 9/19/2025 | 4.16 USD |
| 9/18/2025 | 4.04 USD |
| 9/17/2025 | 3.96 USD |
| 9/16/2025 | 4.02 USD |
| 9/15/2025 | 3.94 USD |
| 9/12/2025 | 3.92 USD |
| 9/11/2025 | 4.02 USD |
| 9/10/2025 | 4.04 USD |
| 9/9/2025 | 4.01 USD |
| 9/8/2025 | 4.08 USD |
| 9/5/2025 | 4.06 USD |
| 9/4/2025 | 4.10 USD |
| 9/3/2025 | 4.04 USD |
| 9/2/2025 | 4.11 USD |
| 8/29/2025 | 4.22 USD |
| 8/28/2025 | 4.23 USD |
| 8/27/2025 | 4.25 USD |
| 8/26/2025 | 4.26 USD |
| 8/25/2025 | 4.20 USD |
| 8/22/2025 | 4.38 USD |
| 8/21/2025 | 4.11 USD |
| 8/20/2025 | 4.15 USD |
| 8/19/2025 | 4.12 USD |
| 8/18/2025 | 4.21 USD |
| 8/15/2025 | 4.17 USD |
| 8/14/2025 | 4.12 USD |
| 8/13/2025 | 4.30 USD |
| 8/12/2025 | 4.15 USD |
| 8/11/2025 | 4.04 USD |
| 8/8/2025 | 3.96 USD |
| 8/7/2025 | 3.87 USD |
| 8/6/2025 | 3.26 USD |
KORU Medical Systems Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
KORU Medical Systems Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 11.00 | 12.00 | 12.00 | 15.00 | 17.00 | 23.00 | 24.00 | 23.00 | 27.00 | 28.00 | 33.00 | 41.00 | 48.00 | 56.00 | 64.00 |
| 14.29 | 37.50 | 9.09 | – | 25.00 | 13.33 | 35.29 | 4.35 | -4.17 | 17.39 | 3.70 | 17.86 | 24.24 | 17.07 | 16.67 | 14.29 |
| 62.50 | 54.55 | 58.33 | 58.33 | 60.00 | 58.82 | 60.87 | 58.33 | 56.52 | 55.56 | 57.14 | 63.64 | 60.98 | 60.98 | 60.98 | 60.98 |
| 5.00 | 6.00 | 7.00 | 7.00 | 9.00 | 10.00 | 14.00 | 14.00 | 13.00 | 15.00 | 16.00 | 21.00 | 25.00 | 29.27 | 34.15 | 39.02 |
| 1.00 | 1.00 | 1.00 | – | 1.00 | 1.00 | – | -1.00 | -7.00 | -10.00 | -10.00 | -6.00 | -2.00 | -12.00 | -14.00 | -15.00 |
| 12.50 | 9.09 | 8.33 | – | 6.67 | 5.88 | – | -4.17 | -30.43 | -37.04 | -35.71 | -18.18 | -4.88 | -25.00 | -25.00 | -23.44 |
| – | – | – | – | 1.00 | – | – | -1.00 | -4.00 | -8.00 | -13.00 | -6.00 | -2.00 | -2.00 | 1.00 | 4.00 |
| – | – | – | – | – | – | – | – | 300.00 | 100.00 | 62.50 | -53.85 | -66.67 | – | -150.00 | 300.00 |
| 36.66 | 38.08 | 38.01 | 37.79 | 38.65 | 39.03 | 39.73 | 43.73 | 44.57 | 45.37 | 45.67 | 45.91 | 46.19 | 46.19 | 46.19 | 46.19 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales KORU Medical Systems generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue KORU Medical Systems retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare KORU Medical Systems's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares KORU Medical Systems has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against KORU Medical Systems's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
KORU Medical Systems stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
KORU Medical Systems Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
KORU Medical Systems business model & stock analysis
KORU Medical Systems SWOT Analysis
Strengths
Repro Med Systems Inc (RMS) benefits from several strengths that contribute to its success in the market. One of its key strengths is its proprietary product portfolio, which includes the innovative Freedom infusion system. This product offers unique advantages such as portability, disposability, and ease of use, giving RMS a competitive edge.
Another strength of RMS is its strong market presence and established customer base. The company has built solid relationships with healthcare providers and distributors, which helps in generating recurring revenue and ensures a steady stream of sales.
Weaknesses
Despite its strengths, RMS also faces certain weaknesses that need to be addressed. One weakness is its dependency on a limited number of key suppliers for critical components of its products. Any disruptions in the supply chain can have a significant impact on production and delivery timelines.
Additionally, RMS has a relatively small product portfolio compared to some of its competitors. This narrow product range limits the company's ability to cater to diverse customer needs and potentially hinders its market expansion efforts.
Opportunities
The healthcare industry is experiencing significant growth, presenting ample opportunities for RMS. The increasing prevalence of chronic diseases and the rising elderly population create a higher demand for home-based medical devices, such as RMS' infusion systems. By capitalizing on this trend, RMS can expand its customer base and increase its market share.
Another opportunity for RMS lies in the emerging markets, where the demand for medical devices is steadily growing. By strategically targeting these markets and adapting its products to meet local requirements, RMS can tap into new revenue streams and achieve global expansion.
Threats
RMS faces several threats that could potentially impact its business. One major threat is intense competition from other medical device manufacturers. The healthcare industry is highly competitive, and RMS needs to continuously innovate and differentiate its products to stay ahead of rivals.
Additionally, regulatory challenges pose a threat to RMS's operations. Compliance with strict regulations and obtaining necessary approvals can be time-consuming and costly. Any delays in obtaining regulatory approvals can hinder product launches and impede market growth.
KORU Medical Systems Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
KORU Medical Systems Segments
KORU Medical Systems Revenue by Region
3 Years
5 Years
Max
Details
KORU Medical Systems Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
KORU Medical Systems historical P/E ratio, EBIT multiple, and P/S ratio
KORU Medical Systems annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
KORU Medical Systems shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current KORU Medical Systems forecasts and price targets in August 2026
Analyst Price Targets 2026KORU Medical Systems Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 3/13/2026 | Maintained | Buy | 59 | |
| 3/13/2026 | Maintained | Buy | – | |
| 12/22/2025 | Maintained | Buy | – | |
| 12/17/2025 | Maintained | Buy | 59 | |
| 8/7/2025 | Maintained | Neutral | 51 | |
| 5/8/2025 | Maintained | Neutral | 51 | |
| 2/14/2025 | Downgrade | OverweightNeutral | 51 | |
| 1/17/2025 | Maintained | Buy | – | |
| 1/14/2025 | Maintained | Buy | – | |
| 11/14/2024 | Maintained | Overweight | 51 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
KORU Medical Systems Earnings Calls
KORU Medical Systems Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2026 | -0.02USD | - | 11.84 MUSD | - | 2026 Q2 |
| 5/6/2026 | -0.02USD | - | 11.51 MUSD | - | 2026 Q1 |
| 3/12/2026 | -0.02USD | - | 11.04 MUSD | - | 2025 Q4 |
| 11/13/2024 | -0.04USD | - | 7.83 MUSD | - | 2024 Q3 |
| 11/7/2023 | -0.04USD | - | 8.14 MUSD | - | 2023 Q3 |
| 8/1/2023 | -0.05USD | - | 7.54 MUSD | - | 2023 Q2 |
| 5/2/2023 | -0.05USD | - | 7.20 MUSD | - | 2023 Q1 |
| 2/28/2023 | -0.06USD | - | 7.45 MUSD | - | 2022 Q4 |
| 11/9/2022 | -0.05USD | - | 6.88 MUSD | - | 2022 Q3 |
| 8/3/2022 | -0.07USD | - | 6.38 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the KORU Medical Systems stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
KORU Medical Systems shareholder structure
| % | Name |
|---|---|
21.16448% | |
13.72262% | |
6.42979% | |
2.91549% | |
1.95731% | |
1.89761% |
KORU Medical Systems Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
17.79% | SEC ↗ | |
17.79% | SEC ↗ | |
12.62% | SEC ↗ | |
11.54% | SEC ↗ | |
10.93% | SEC ↗ | |
8.50% | SEC ↗ | |
8.31% | SEC ↗ | |
8.03% | SEC ↗ | |
7.90% | SEC ↗ | |
6.41% | SEC ↗ |
KORU Medical Systems Executives and Management Board
9 members · avg. age 59 · 33 % women
Ms. Linda Tharby (53)
President, Chief Executive Officer
725,169.00 USD
Management
Ms. Karen Fisher (56)
Chief Financial Officer, Secretary, Treasurer
Mr. Manuel Marques (49)
Chief Operating Officer
Mr. Brian Case
Chief Technology Officer
Board of Directors
Mr. James Beck (74)
Independent Director · since 2018
Mr. R. John Fletcher (76)
Independent Chairman of the Board
Mr. Joseph Manko (56)
Independent Director
Mr. Shahriar Matin (47)
Independent Director
Dr. Donna French (57)
Independent Director
KORU Medical Systems Supply Chain
KORU Medical Systems Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.60 | 0.66 | -0.19 |
Frequently asked questions about KORU Medical Systems
The business model of Repro Med Systems Inc is focused on the development, manufacturing, and marketing of innovative medical devices. The company specializes in the design of proprietary infusion technologies, primarily catering to patients with chronic diseases and conditions. Repro Med Systems Inc aims to provide superior and convenient solutions for patients requiring infusion therapy, resulting in improved quality of life and enhanced healthcare outcomes. With their expertise in the field, the company continually strives to meet the evolving needs of patients and healthcare professionals alike, positioning itself as a leader in the medical device industry.
Repro Med Systems Inc, also known as RMS Medical Products, primarily operates in the medical devices industry. With a focus on innovative medical solutions, RMS specializes in the development, manufacture, and distribution of portable and easy-to-use medical devices. These devices primarily assist with the administration of fluids and medications in various healthcare settings. The company's products, like the Freedom Syringe Infusion System, are designed to enhance patients' quality of life by providing effective and convenient treatment options. As a leader in this industry, Repro Med Systems Inc continues to provide cutting-edge solutions that positively impact healthcare delivery.
The main competitors of Repro Med Systems Inc in the market include other medical device companies such as Becton, Dickinson and Company (BD), Baxter International Inc., and Teleflex Incorporated. These companies also offer a range of medical devices and solutions, competing with Repro Med Systems Inc in the same market segment.
Repro Med Systems Inc, commonly known as RMS Medical Products, is a leading medical device company specializing in the development and commercialization of advanced infusion solutions. With a rich history spanning over 30 years, RMS has established itself as a trusted provider of innovative medical products that improve patient outcomes. The company's flagship product, the FREEDOM Syringe Infusion System, revolutionizes the way medication is delivered, offering patients a convenient and effective alternative to traditional infusion methods. As a pioneer in the industry, Repro Med Systems Inc continues to invest in research and development, ensuring its products remain at the forefront of medical advancements.
Repro Med Systems Inc, a renowned medical device company, has achieved significant milestones throughout its existence. Over the years, the company has successfully developed and marketed innovative medical products, firmly establishing itself as a leader in the industry. Repro Med Systems Inc has gained recognition for its proprietary technology, particularly its market-leading primary product, the FREEDOM60® and FreedomEdge™ Syringe Infusion Systems. These devices have revolutionized the way patients receive medication, offering enhanced convenience, safety, and precision. With a strong commitment to research and development, Repro Med Systems Inc has continually expanded its product portfolio, meeting the evolving needs of healthcare providers and patients alike.
Repro Med Systems Inc, also known as RMS Medical Products, is primarily present in various countries and regions worldwide. The company operates globally, with a significant presence in North America, including the United States and Canada. Additionally, Repro Med Systems Inc has extended its reach to several international markets, such as Europe, particularly in the United Kingdom, Germany, France, Italy, and Spain. Moreover, the company has established a strong presence in the Asia-Pacific region, including Japan, China, and Australia. With its global presence, Repro Med Systems Inc serves a diverse customer base across different continents.
Repro Med Systems Inc, a leading stock in the healthcare sector, represents core values of innovation, excellence, and dedication to patient care. With their robust corporate philosophy, Repro Med Systems Inc strives to provide cutting-edge medical devices and solutions that enhance the quality of life for patients. The company's mission revolves around delivering safe, reliable, and efficient medical technologies, ensuring positive medical outcomes and improving patient experiences. Repro Med Systems Inc's commitment to customer satisfaction, continuous improvement, and ethical business practices truly sets them apart in the industry. By embracing these values, Repro Med Systems Inc establishes itself as a trusted and valued healthcare provider.
Analysts currently set an average price target of 6.73 USD for the KORU Medical Systems stock (median: 7.14 USD), implying +63.4 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the KORU Medical Systems stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect KORU Medical Systems to generate revenue of 48.69 M USD and earnings per share of -0.04 USD.
Converted at the current exchange rate, the KORU Medical Systems share trades at 3.57 EUR (4.12 USD).
The KORU Medical Systems share (KRMD) is listed on 1 stock exchanges, including: NASDAQ (KRMD).
Repro Med Systems Inc (RMS) is a leading provider of medical devices and consumables for infusion and pain therapy. The company was founded in 1980 and is headquartered in Chester, New York. RMS's business model focuses on three main areas: infusion pumps, pain therapy systems, and consumables. One of RMS's key product lines is infusion pumps. The company offers a wide range of portable and stationary infusion pumps used in the administration of fluids and medications to patients. These devices enable accurate dosing and monitoring of infusions, contributing to the safety and effectiveness of treatment. Another important area for RMS is pain therapy. The company offers systems for controlled pain delivery, allowing effective pain relief for patients with acute or chronic pain. RMS provides both portable and stationary pain therapy systems that enable accurate dosing and individual adjustment of pain medications. Consumables such as catheters, syringes, and tubes are also an important part of RMS's offering. The company provides high-quality and reliable products specifically designed for use with their infusion pumps and pain therapy systems. RMS focuses on developing and marketing innovative medical devices and consumables that contribute to the quality and efficiency of patient care. The company works closely with physicians, nurses, and other healthcare providers to understand patient needs and provide the best possible solutions. The company sells its products in the US and worldwide through a network of dealers, distributors, and online platforms. RMS has a strong presence in North America but also operates in Europe, Asia, and other regions. The company places great value on customer satisfaction and offers comprehensive customer support and training. Overall, RMS is an established and successful provider of medical devices and consumables for infusion and pain therapy. The company benefits from a strong market position, innovative products, and an experienced management team. With its broad product line and strong distribution network, RMS is well positioned to continue growing and expanding in the future.
The expected revenue of KORU Medical Systems is 48.69 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of KORU Medical Systems is -2.03 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of KORU Medical Systems is currently -93.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the KORU Medical Systems stock.
The price-to-sales ratio (P/S) of KORU Medical Systems is currently 3.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the KORU Medical Systems stock.
The Eulerpool Quality Score for KORU Medical Systems is 2/10.
The ISIN of KORU Medical Systems is US7599101026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of KORU Medical Systems is 913004. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of KORU Medical Systems is KRMD. The ticker symbol is used to trade KORU Medical Systems shares on the stock exchange.
KORU Medical Systems paid dividends every year for the past 0 years.
KORU Medical Systems is assigned to the 'Health' sector.
The dividends of KORU Medical Systems are distributed in USD.
KORU Medical Systems stock
KORU Medical Systems Peer Group
KORU Medical Systems Ticker
KORU Medical Systems FIGI
All fundamentals and in-depth analysis of KORU Medical Systems
Our stock analysis for KORU Medical Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of KORU Medical Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.